Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia


Deficiency of protein C (PC), protein S (PS), antithrombin III (AT III), and homozygosity or combined heterozygosity for Factor V Leiden (FVL) and Factor II (FII) 20210A mutation represent severe hereditary thrombophilia (SHT) and are associated with a higher risk of early-onset venous thromboembolism (VTE). In literature, few papers have described the efficacy and safety of therapy with direct oral anticoagulants (DOACs) in VTE occurring in patients with SHT. In our setting, we identified 8 patients who have suffered from early-onset VTE and underwent therapy with DOACs (6 rivaroxaban, 2 apixaban). Among them, 2 AT III deficiency, 2 PC deficiency, 3 PS deficiency, 1 combined heterozygosity for FVL, and FII 20210A were detected. During the follow-up, neither recurrences of VTE nor hemorrhagic episodes were observed. This report describes the efficacy and safety of therapy with anti-Xa in the treatment and secondary prophylaxis of VTE in patients with SHT.



PlumX Metrics


Download data is not yet available.


Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015;114:885-9. DOI:

Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006;43:249-90. DOI:

Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808. DOI:

Einstein Investigators; Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510. DOI:

van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75. DOI:

Undas A, Goralczyk T. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinol 2017;28:438-42. DOI:

Schulman S, Eriksson H, Goldhaber S, et al. Influence of thrombophilia on the efficacy of dabigatran versus warfarin for the extended treatment of acute venous thromboembolism in RE-MEDY™. Blood 2014;124:A1544. DOI:

Alameddinea R, Nassabeina R, Le Galb G, et al. Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. Thromb Res 2020;185:72-7. DOI:

Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A. PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res 2014;134:199-201. DOI:

Boey JP, Jolley A, Nicholis C, et al. Novel protein C gene mutation in a compound heterozygote resulting in cathastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate. Br J Haematol 2016;172:811-3. DOI:

Hermans C, Eeckhoudt S, Lambert C. Dabigatran etexilate (Pradaxa(R)) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost 2012;107:1189-91. DOI:

Brief Reports
Venous thromboembolism, hereditary thrombophilia, direct oral anticoagulants.
  • Abstract views: 65

  • PDF: 62
  • HTML: 0
How to Cite
Madonna, P., Guida, A., Coppola, M. G., Tirelli, P., & Grasso, E. (2021). Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia. Italian Journal of Medicine, 15(1).